


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) An N-phenyl-(2R,5S)dimethylpiperazine derivative represented by the following general formula. (I) or a salt thereof:



wherein the symbols in the formula have the following meanings:

R¹: Cl, F, Br, -CN, -CH₃, -CF₃, or -O-lower alkyl

R²: H, F, or -OCH₃

R³: H or lower alkyl

Cy: ~~a group represented by the following a) to e) groups~~

a) ~~benzene (monosubstituted by -CN, -COCH₃, or -OCF₃)~~

b) ~~benzene (phenyl monosubstituted by a group selected from -SCF₃, -OCH₃, -NO₂,~~

~~and 1-CN-cyclopropyl-1-yl, or disubstituted by groups one of which is -CN and another one of which is selected from -OCF₃, -OCH₃, -CH₃, -CF₃, and -Cl)~~

e) ~~pyridine (substituted by CN, CF₃, halogen, OCH₂CF₃, or cyclopropyl)~~
pyrimidine (~~monosubstituted~~ substituted by a lower alkyl or a cyclopropyl group.)

e) ~~imidazopyridine (optionally substituted by lower alkyl)~~

~~benzopyrazine (optionally substituted by lower alkyl or cycloalkyl)~~

~~quinoxaline (optionally substituted by O-lower alkyl or morpholinyl)~~

~~quinoline (optionally substituted by lower alkyl or morpholinyl)~~

~~benzothiazole (optionally substituted by lower alkyl)~~

~~isoquinoline~~

~~benzothiadiazole (optionally substituted by lower alkyl)~~

~~indolidine or tetrahydrobenzofuran (optionally substituted by oxo)~~

provided that, when R¹ is ~~CF₃~~ and R² is H, Cy represents a group other than the e) group.

2. (Currently amended) The N-phenyl-(2R,5S)dimethylpiperazine derivative or salt thereof according to claim 1, wherein R¹ is Cl, F, Br, CF₃, ~~CN~~, ~~CH₃~~, or -O-lower alkyl, R² is H or F, and R³ is H.

3. (Cancelled)

4. (Currently amended) A compound selected from (2R,5S) -4- (3-chloro-4-cyanophenyl)-N- (2-cyclopropylpyrimidin-5-yl) -2,5-dimethylpiperazine-1-carboxamide ; (2R,

~~5S) 4-(3-chloro-4-cyanophenyl)-N-(6-cyano-3-pyridyl)-2,5-dimethylpiperazine-1-carboxamide; (2R, 5S)-4-(4-cyano-3-methoxyphenyl)-2,5-dimethyl-N-(6-trifluoromethyl-3-pyridyl)piperazine-1-carboxamide; (2R, 5S)-4-(3-bromo-4-cyanophenyl)-2,5-dimethyl-N-(6-trifluoromethyl-3-pyridyl)piperazine-1-carboxamide; and (2R, 5S)-4-(4-cyano-3-trifluoromethylphenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide, or a salt thereof.~~

5. (Original) A pharmaceutical composition comprising the N-phenyl-(2R,5S)dimethylpiperazine derivative according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

6. (Original) A prostate cancer-treating agent comprising a therapeutically effective amount of the N-phenyl(2R,5S)dimethylpiperazine derivative according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

7. (Cancelled)

8. (Original) A method for treating prostate cancer which comprises administering a therapeutically effective amount of the N-phenyl-(2R,5S)dimethylpiperazine derivative according to claim 1 or a pharmaceutically acceptable salt thereof.

9. (Cancelled)
10. (new) A compound selected from
- (2R, 5S)-4- [4-cyano-3-(trifluoromethyl)phenyl] -2, 5-dimethyl-N-(2-methylpyrimidin-5-yl)piperazine-1-carboxamide;
- (2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2-cyclopropylpyrimidin-5-yl)-2, 5-dimethylpiperazine -1-carboxamide;
- (2R,5S)-4-(3-chloro-4-cyanophenyl)-2,5-dimethyl-N-(2-methylpyrimidin-5-yl)piperazine-1-carboxamide; (2R, 5S)-4-(3-chloro-4-cyanophenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2, 5-dimethylpiperazine-1-carboxamide;
- (2R,5S)-4-(4-cyano-3-methoxyphenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide;
- (2R,5S)-4-(4-cyano-3-fluoro-5-methoxyphenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide;
- (2R, 5S)-4-(3-bromo-4-cyanophenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide; and
- (2R, 5S)-4-(3-bromo-4-cyanophenyl)-2,5-dimethyl-N-(2-methylpyrimidin-5-yl)piperazine-1-carboxamide, or a salt thereof.